Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination

doi:10.1161/HYPERTENSIONAHA.121.17316

. 2021 Jun;77(6):e56-e57.

doi: 10.1161/HYPERTENSIONAHA.121.17316. Epub 2021 Mar 25.

Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination

Sylvain Meylan¹, Françoise Livio², Maryline Foerster³, Patrick James Genoud⁴, François Marguet⁴, Gregoire Wuerzner⁵; CHUV COVID Vaccination Center

Affiliations

¹ Department of Medicine, Infectious Diseases Service, University Hospital Lausanne and University of Lausanne, Switzerland (S.M.).
² Service of Clinical Pharmacology, Department of Laboratories (F.L.), Lausanne University Hospital and University of Lausanne, Switzerland.
³ Emergency Department (M.F.), University Hospital of Lausanne, Switzerland.
⁴ Nursing Directorate (P.J.G., F.M.), University Hospital of Lausanne, Switzerland.
⁵ Department of Medicine, Service of Nephrology and Hypertension (G.W.), Lausanne University Hospital and University of Lausanne, Switzerland.

PMID: 33764160
PMCID: PMC8115421
DOI: 10.1161/HYPERTENSIONAHA.121.17316

Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination

Sylvain Meylan et al. Hypertension. 2021 Jun.

. 2021 Jun;77(6):e56-e57.

doi: 10.1161/HYPERTENSIONAHA.121.17316. Epub 2021 Mar 25.

Authors

Sylvain Meylan¹, Françoise Livio², Maryline Foerster³, Patrick James Genoud⁴, François Marguet⁴, Gregoire Wuerzner⁵; CHUV COVID Vaccination Center

Affiliations

¹ Department of Medicine, Infectious Diseases Service, University Hospital Lausanne and University of Lausanne, Switzerland (S.M.).
² Service of Clinical Pharmacology, Department of Laboratories (F.L.), Lausanne University Hospital and University of Lausanne, Switzerland.
³ Emergency Department (M.F.), University Hospital of Lausanne, Switzerland.
⁴ Nursing Directorate (P.J.G., F.M.), University Hospital of Lausanne, Switzerland.
⁵ Department of Medicine, Service of Nephrology and Hypertension (G.W.), Lausanne University Hospital and University of Lausanne, Switzerland.

PMID: 33764160
PMCID: PMC8115421
DOI: 10.1161/HYPERTENSIONAHA.121.17316

No abstract available

Keywords: headache; humans; hypertension; vaccines; vital signs.

PubMed Disclaimer

Comment in

Hypertensive Crisis Following COVID-19 Vaccination.
Khani E, Entezari-Maleki T. Khani E, et al. J Clin Pharmacol. 2022 Aug;62(8):1047-1048. doi: 10.1002/jcph.2037. Epub 2022 Feb 27. J Clin Pharmacol. 2022. PMID: 35147213 Free PMC article. No abstract available.

Cited by

Safety pharmacology of human endogenous retrovirus-enveloped baculoviral DNA vaccines against SARS-CoV-2 in Sprague-Dawley rats and beagle dogs.
Park SJ, Seo JW, Han KH, Lee BS, Lee C, Kim BY, Ko KC, Kim YB. Park SJ, et al. Vaccine X. 2024 Aug 3;20:100545. doi: 10.1016/j.jvacx.2024.100545. eCollection 2024 Oct. Vaccine X. 2024. PMID: 39221182 Free PMC article.
Evaluation of blood pressure variation in recovered COVID-19 patients at one-year follow-up: a retrospective cohort study.
Azami P, Vafa RG, Heydarzadeh R, Sadeghi M, Amiri F, Azadian A, Khademolhosseini A, Yousefi M, Montaseri M, Hosseini N, Hosseini SA, Kojuri J. Azami P, et al. BMC Cardiovasc Disord. 2024 May 7;24(1):240. doi: 10.1186/s12872-024-03916-w. BMC Cardiovasc Disord. 2024. PMID: 38714940 Free PMC article.
Immunogenicity and Safety of Half-Dose Heterologous mRNA-1273 Booster Vaccination for Adults Primed with the CoronaVac^® and ChAdOx1-S Vaccines for SARS-CoV-2.
Putri ND, Zhafira AS, Wicaksana P, Sinto R, Hanafi G, Wiyono L, Prayitno A, Karyanti MR, Naibaho ML, Febrina F, Sukandar H, Setiawaty V, Mursinah M, Putra AR, Wibowo H, Sundoro J, Satari HI, Oktavia D, Multihartina P, Harbuwono DS, Hadinegoro SR. Putri ND, et al. Vaccines (Basel). 2024 Mar 22;12(4):344. doi: 10.3390/vaccines12040344. Vaccines (Basel). 2024. PMID: 38675727 Free PMC article.
Genotoxicity and safety pharmacology of the rVSVInd(GML)-mspSGtc vaccine against SARS-CoV-2 in Sprague-Dawley rats and Beagle dogs.
Park SJ, Park H, Back SM, Lee YJ, Seo JW, Kim D, Lee JH, Kwak C, Han KH, Son HY, Kim YB. Park SJ, et al. Arch Toxicol. 2024 Jul;98(7):2185-2197. doi: 10.1007/s00204-024-03746-x. Epub 2024 Apr 12. Arch Toxicol. 2024. PMID: 38607375
Exploring the reported adverse effects of COVID-19 vaccines among vaccinated Arab populations: a multi-national survey study.
Amer SA, Al-Zahrani A, Imam EA, Ishteiwy EM, Djelleb IF, Abdullh LR, Ballaj D, Amer YA, El-Sokkary RH, Elshabrawy AM, Eskander G, Shah J, Raza ML, ALsafa AMAA, Ali HT, Fawzy HM. Amer SA, et al. Sci Rep. 2024 Feb 27;14(1):4785. doi: 10.1038/s41598-024-54886-0. Sci Rep. 2024. PMID: 38413637 Free PMC article.

See all "Cited by" articles

References

1. Thompson BG, Brown RD, Jr, Amin-Hanjani S, Broderick JP, Cockroft KM, Connolly ES, Jr, Duckwiler GR, Harris CC, Howard VJ, Johnston SC, et al. ; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention; American Heart Association; American Stroke Association. Guidelines for the management of patients with unruptured intracranial aneurysms: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2368–2400. doi: 10.1161/STR.0000000000000070 - PubMed
1. Thomas O, Shipman KE, Day K, Thomas M, Martin U, Dasgupta I. Prevalence and determinants of white coat effect in a large UK hypertension clinic population. J Hum Hypertens. 2016;30:386–391. doi: 10.1038/jhh.2015.95 - PubMed
1. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. Morbidity Mortal Wkly Rep. 2021;70:46–51. doi: 10.15585/mmwr.mm7002e1 - PMC - PubMed
1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577 - PMC - PubMed
1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. ; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389 - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Thompson BG, Brown RD, Jr, Amin-Hanjani S, Broderick JP, Cockroft KM, Connolly ES, Jr, Duckwiler GR, Harris CC, Howard VJ, Johnston SC, et al. ; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention; American Heart Association; American Stroke Association. Guidelines for the management of patients with unruptured intracranial aneurysms: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2368–2400. doi: 10.1161/STR.0000000000000070 - PubMed

[2] Thompson BG, Brown RD, Jr, Amin-Hanjani S, Broderick JP, Cockroft KM, Connolly ES, Jr, Duckwiler GR, Harris CC, Howard VJ, Johnston SC, et al. ; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention; American Heart Association; American Stroke Association. Guidelines for the management of patients with unruptured intracranial aneurysms: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2368–2400. doi: 10.1161/STR.0000000000000070 - PubMed

[3] Thomas O, Shipman KE, Day K, Thomas M, Martin U, Dasgupta I. Prevalence and determinants of white coat effect in a large UK hypertension clinic population. J Hum Hypertens. 2016;30:386–391. doi: 10.1038/jhh.2015.95 - PubMed

[4] Thomas O, Shipman KE, Day K, Thomas M, Martin U, Dasgupta I. Prevalence and determinants of white coat effect in a large UK hypertension clinic population. J Hum Hypertens. 2016;30:386–391. doi: 10.1038/jhh.2015.95 - PubMed

[5] CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. Morbidity Mortal Wkly Rep. 2021;70:46–51. doi: 10.15585/mmwr.mm7002e1 - PMC - PubMed

[6] CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. Morbidity Mortal Wkly Rep. 2021;70:46–51. doi: 10.15585/mmwr.mm7002e1 - PMC - PubMed

[7] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577 - PMC - PubMed

[8] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577 - PMC - PubMed

[9] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. ; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389 - PMC - PubMed

[10] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. ; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389 - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination

Affiliations

Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination

Authors

Affiliations

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous